Ask The Recruiter

Quince Therapeutics, Inc.

Funding reported, $115M, last update 2 months ago

Pharma biotech · Headquarters United States

Everything we hold on Quince Therapeutics, Inc., newest first. Every line links to the filing or report it came from.

5 updates tracked
$115M disclosed funding
1 leadership change
31 Dec 2023 tracked since
United States where
  1. 2026-06-11
    Headcount Not Stated Growing and expanding

    Quince Therapeutics, Inc. raised $114.7M in a private placement

    Quince Therapeutics, Inc. reported a $114.7M private placement to the SEC on 2026-06-11, listing an address in CA. The filing records the money only; it names no roles and no hiring plan.

    United States · $115M raised · Official Filing · SEC EDGAR (Form D)

  2. 2026-02-02
    Headcount Not Stated Leadership moves

    Quince Therapeutics, Inc. 8-K filing (Item 5.02): officer or director change

    Five board members resign at Quince Therapeutics in South San Francisco; the announcement does not name replacements.

    United States · Official Filing · SEC EDGAR

  3. 2025-12-31
    Pay Change Pay and benefits

    QUINCE THERAPEUTICS, INC.: $2,411,125 total compensation for the principal executive officer, fiscal year ended 2025-12-31

    Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.

    United States · Official Filing · SEC EDGAR (pay-versus-performance)

  4. 2024-12-31
    Pay Change Pay and benefits

    QUINCE THERAPEUTICS, INC.: $2,732,125 total compensation for the principal executive officer, fiscal year ended 2024-12-31

    Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.

    United States · Official Filing · SEC EDGAR (pay-versus-performance)

  5. 2023-12-31
    Pay Change Pay and benefits

    QUINCE THERAPEUTICS, INC.: $1,330,500 total compensation for the principal executive officer, fiscal year ended 2023-12-31

    Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.

    United States · Official Filing · SEC EDGAR (pay-versus-performance)

Cite this pageQuince Therapeutics, Inc.. Talent Intelligence Tracker, AskTheRecruiter.com. Accessed Aug 20, 2026. https://asktherecruiter.com/blog/talent-intelligence-tracker/company/quince-therapeutics/ Licensed CC BY 4.0; every record links to the document behind it.

The read-through on each line is our interpretation. The headline and figures come from the linked source. Data licensed CC BY 4.0. Back to the tracker